Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
NEW YORK (Reuters Health) – A systematic review and meta-analysis provides “reasonable” support for the current practice of giving adjuvant therapy to patients with resected biliary tract cancer…
NEW YORK (Reuters Health) – Progression-free survival (PFS) is significantly longer in women with recurrent ovarian cancer when bevacizumab is added to chemotherapy, a multicenter team reports in…
NEW YORK (Reuters Health) – Cancer patients given pegfilgrastim experience less bone pain if they take naproxen 500 mg twice daily for about a week, according to the…
NEW YORK (Reuters Health) – Adding trastuzumab (Herceptin) to standard chemotherapy for HER2-positive early breast cancer significantly reduces recurrence risk and improves overall survival, but it also increases…
NEW YORK (Reuters Health) – Adding cladribine to the standard induction regimen for adults with acute myeloid leukemia (AML) increases the complete remission rate and consequent survival, a…
NEW YORK (Reuters Health) – Adding bevacizumab (Avastin, Genentech) to standard carboplatin and paclitaxel chemotherapy offers little clinical benefit in patients aged 65 and older with non-small cell…
NEW YORK (Reuters Health) – Older patients with small localized kidney tumors treated with partial nephrectomy live longer than those treated with radical nephrectomy, a new study suggests.…
NEW YORK (Reuters Health) – A meta-analysis of individual patient data found no differences in overall survival, progression-free survival, and objective response rate between cisplatin- and carboplatin-based chemotherapy…
NEW YORK (Reuters Health) – Adjuvant tamoxifen after surgery and radiation reduces subsequent ipsilateral and contralateral breast cancers in women with estrogen-receptor (ER)-positive ductal carcinoma in situ (DCIS),…
NEW YORK (Reuters Health) – A multicenter center study has shown that adding cetuximab to neoadjuvant chemotherapy and preoperative radiotherapy improves overall survival after excision of high-risk rectal…
